Sight Sciences IncNASDAQ:SGHT
- LAST PRICE3.9900
- TODAY'S CHANGE (%)0.0800 (2.0460%)
- Bid / Lots3.7500/ 4
- Ask / Lots4.4000/ 8
- Open / Previous Close4.0300 / 3.9100
- Day Range
- 52 Week Range
- Volume71,626
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SGHT |
|---|---|---|
| 09:32 ET | 608 | 4.08 |
| 09:42 ET | 300 | 3.95 |
| 09:53 ET | 100 | 3.98 |
| 10:06 ET | 100 | 3.965 |
| 10:08 ET | 358 | 3.98 |
| 10:11 ET | 1154 | 3.98 |
| 10:15 ET | 499 | 4 |
| 10:18 ET | 500 | 3.99 |
| 10:24 ET | 100 | 3.98 |
| 10:27 ET | 100 | 3.98 |
| 10:31 ET | 400 | 3.97 |
| 10:36 ET | 223 | 3.969 |
| 10:42 ET | 119 | 3.97 |
| 10:45 ET | 200 | 3.96 |
| 10:51 ET | 200 | 3.98 |
| 11:00 ET | 100 | 3.995 |
| 11:12 ET | 300 | 3.97 |
| 11:25 ET | 535 | 3.985 |
| 11:27 ET | 312 | 3.98 |
| 11:39 ET | 750 | 3.97 |
| 11:43 ET | 1300 | 3.975 |
| 11:45 ET | 840 | 4 |
| 11:50 ET | 100 | 4.01 |
| 11:52 ET | 100 | 4 |
| 11:54 ET | 1478 | 4.01 |
| 11:57 ET | 234 | 4.015 |
| 11:59 ET | 200 | 4.01 |
| 12:06 ET | 338 | 4.02 |
| 12:12 ET | 1200 | 4 |
| 12:14 ET | 259 | 4.005 |
| 12:17 ET | 200 | 4 |
| 12:19 ET | 100 | 4.01 |
| 12:24 ET | 820 | 4.01 |
| 12:26 ET | 867 | 3.995 |
| 12:30 ET | 500 | 4 |
| 12:35 ET | 200 | 3.995 |
| 12:42 ET | 700 | 4.005 |
| 12:44 ET | 200 | 4.005 |
| 12:46 ET | 3300 | 3.995 |
| 12:48 ET | 300 | 3.995 |
| 12:50 ET | 526 | 3.995 |
| 12:51 ET | 5639 | 4.02 |
| 12:53 ET | 406 | 4.015 |
| 12:55 ET | 1281 | 4.015 |
| 12:57 ET | 1470 | 4.01 |
| 01:00 ET | 22260 | 3.99 |
Nov 19, 2024
Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference, from 4:05PM ET on Tuesday Nov 19, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 11, 2024
DJ Sight Sciences Is Maintained at Equal-Weight by Morgan Stanley, from 7:31AM ET on Monday Nov 11, 2024 by Dow Jones
7:31AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 8, 2024
DJ Sight Sciences Price Target Cut to $5.50/Share From $6.00 by Piper Sandler, from 9:04AM ET on Friday Nov 08, 2024 by Dow Jones
9:04AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow JonesPress Release: Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sight Sciences Inc | 202.0M | -3.9x | --- |
Utah Medical Products Inc | 221.0M | 15.3x | +2.27% |
InfuSystem Holdings Inc | 188.4M | 132.1x | --- |
Pro-Dex Inc | 166.2M | 33.3x | -9.17% |
Pulmonx Corp | 255.1M | -4.4x | --- |
KORU Medical Systems Inc | 185.0M | -15.2x | --- |
Company Information
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma and the SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids in adult patients with evaporative dry eye disease due to meibomian gland disfunction.
Contact Information
- Headquarters
- 4040 Campbell Ave,, Suite 100MENLO PARK, CA, United States 94025
- Phone
- 415-889-0550
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Staffan Encrantz
- President, Chief Executive Officer, Co-Founder, Director
- Paul Badawi
- Co-Founder, Chief Technology Officer, Director
- David Badawi
- Chief Financial Officer, Treasurer
- Alison Bauerlein
- Principal Operating Officer, Executive Vice President of Operations
- Brenton Taylor
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $202.0M |
|---|---|
Revenue (TTM) | $79.5M |
Shares Outstanding | 50.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.59 |
EPS | $-1.01 |
Book Value | $2.45 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | 2.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -64.96% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
